Effective, broad spectrum control of virulent bacterial infections using cationic dna liposome complexes combined with bacterial antigens

PLoS Pathogens

Volumn 6, Issue 5, 2010, Pages 1-16

  Ireland, Robin ^a   Olivares Zavaleta, Norma ^a   Warawa, Jonathan M ^a   Gherardini, Frank C ^a   Jarrett, Clayton ^a   Hinnebusch, B Joseph ^a   Belisle, John T ^b   Fairman, Jeffery ^c   Bosio, Catharine M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Juvaris BioTherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CATIONIC LIPOSOME DNA COMPLEX; DRUG CARRIER; INTERLEUKIN 12; INTERLEUKIN 6; MEMBRANE PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; CATION; DNA; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL REPRODUCTION; BACTERIAL VIRULENCE; BRUCELLA ABORTUS; BURKHOLDERIA PSEUDOMALLEI; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FRANCISELLA TULARENSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTECTION; SURVIVAL RATE; TULAREMIA; YERSINIA PESTIS; ANIMAL; BRUCELLOSIS; C57BL MOUSE; CELL CULTURE; CYTOLOGY; GERMFREE ANIMAL; GROWTH, DEVELOPMENT AND AGING; MELIOIDOSIS; MICROBIOLOGY; PATHOGENICITY; PLAGUE; VIRULENCE;

BACTERIA (MICROORGANISMS); BRUCELLA MELITENSIS BIOVAR ABORTUS; BURKHOLDERIA PSEUDOMALLEI; FRANCISELLA TULARENSIS; MURINAE; MUS; YERSINIA PESTIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BRUCELLA ABORTUS; BRUCELLOSIS; BURKHOLDERIA PSEUDOMALLEI; CATIONS; CELLS, CULTURED; DNA; FRANCISELLA TULARENSIS; HUMANS; LIPOSOMES; MACROPHAGES; MALE; MELIOIDOSIS; MICE; MICE, INBRED C57BL; PLAGUE; SPECIFIC PATHOGEN-FREE ORGANISMS; TULAREMIA; VIRULENCE; YERSINIA PESTIS;

EID: 77954052040     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000921     Document Type: Article

References (57)

1. Conlan JW, Chen W, Shen H, Webb A, KuoLee R (2003) Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 34: 239-248.
2. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S (1961) Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 107: 702-714.
3. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D (1966) Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev 30: 542-550.
4. Cross JT, Jacobs RF (1993) Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis 17: 976-980.
5. Overholt EL, Tigertt WD, Kadull PJ, Ward MK, Charkes ND, et al. (1961) An analysis of forty-two cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics. Am J Med 30: 785-806.
6. Risi GF, Pombo DJ (1995) Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options. Clin Infect Dis 20: 174-175.
7. Gowen BB, Fairman J, Dow S, Troyer R, Wong MH, et al. (2009) Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res 81: 37-46.
8. Krieg AM, Love-Homan L, Yi AK, Harty JT (1998) CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 161: 2428-2434.
9. Panchal RG, Ulrich RL, Bradfute SB, Lane D, Ruthel G, et al. (2009) Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis. J Biol Chem 284: 12874-12885.
10. Checroun C, Wehrly TD, Fischer ER, Hayes SF, Celli J (2006) Autophagymediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication. Proc Natl Acad Sci U S A 103: 14578-14583.
11. Chong A, Wehrly TD, Nair V, Fischer ER, Barker JR, et al. (2008) The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression. Infect Immun 76: 5488-5499.
12. Bogdan C, Rollinghoff M, Diefenbach A (2000) The role of nitric oxide in innate immunity. Immunol Rev 173: 17-26.
13. Anthony LS, Morrissey PJ, Nano FE (1992) Growth inhibition of Francisella tularensis live vaccine strain by IFN-gamma-activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. J Immunol 148: 1829-1834.
14. Lindgren H, Stenman L, Tarnvik A, Sjostedt A (2005) The contribution of reactive nitrogen and oxygen species to the killing of Francisella tularensis LVS by murine macrophages. Microbes Infect 7: 467-475.
15. Lindgren H, Stenmark S, Chen W, Tarnvik A, Sjostedt A (2004) Distinct roles of reactive nitrogen and oxygen species to control infection with the facultative intracellular bacterium Francisella tularensis. Infect Immun 72: 7172-7182.
16. Polsinelli T, Meltzer MS, Fortier AH (1994) Nitric oxide-independent killing of Francisella tularensis by IFN-gamma-stimulated murine alveolar macrophages. J Immunol 153: 1238-1245.
17. Elkins KL, Cowley SC, Bosio CM (2007) Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 1105: 284-324.
18. Chiavolini D, Weir S, Murphy JR, Wetzler LM (2008) Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia. Clin Vaccine Immunol 15: 1322-1329.
19. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, et al. (2009) Antigenspecific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A 106: 4343-4348.
20. Dreisbach VC, Cowley S, Elkins KL (2000) Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun 68: 1988-1996.
21. Fulop M, Manchee R, Titball R (1995) Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13: 1220-1225.
22. Thomas RM, Titball RW, Oyston PC, Griffin K, Waters E, et al. (2007) The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect Immun 75: 371-378.
23. Chase JC, Celli J, Bosio CM (2009) Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun 77: 180-195.
24. Cowley SC, Myltseva SV, Nano FE (1996) Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. Mol Microbiol 20: 867-874.
25. Sandstrom G, Sjostedt A, Johansson T, Kuoppa K, Williams JC (1992) Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS. FEMS Microbiol Immunol 5: 201-210.
26. Goodyear A, Kellihan L, Bielefeldt-Ohmann H, Troyer R, Propst K, et al. (2009) Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect Immun 77: 1579-1588.
27. Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW (2009) Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine 27: 4424-4433.
28. Elkins KL, Bosio CM, Rhinehart-Jones TR (1999) Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun 67: 6002-6007.
29. Rozak DA, Gelhaus HC, Smith M, Zadeh M, Huzella L, et al. CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J Immune Based Ther Vaccines 8: 2.
30. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, et al. (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176: 7335-7345.
31. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, et al. (2007) DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448: 501-505.
32. Flak TA, Goldman WE (1999) Signalling and cellular specificity of airway nitric oxide production in pertussis. Cell Microbiol 1: 51-60.
33. Goldman WE, Klapper DG, Baseman JB (1982) Detection, isolation, and analysis of a released Bordetella pertussis product toxic to cultured tracheal cells. Infect Immun 36: 782-794.
34. O'Reilly T, Zak O (1992) Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin Infect Dis 14: 1100-1109.
35. Totemeyer S, Sheppard M, Lloyd A, Roper D, Dowson C, et al. (2006) IFNgamma enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2. J Immunol 176: 4804-4810.
36. Vogel FR (2000) Improving vaccine performance with adjuvants. Clin Infect Dis 30 Suppl 3: S266-270.
37. Bosio CM, Bielefeldt-Ohmann H, Belisle JT (2007) Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol 178: 4538-4547.
38. Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, et al. (2008) Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect Immun 76: 5843-5852.
39. Lopez MC, Duckett NS, Baron SD, Metzger DW (2004) Early activation of NK cells after lung infection with the intracellular bacterium, Francisella tularensis LVS. Cell Immunol 232: 75-85.
40. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, et al. (1999) Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163: 1552-1561.
41. Lindgren H, Shen H, Zingmark C, Golovliov I, Conlan W, et al. (2007) Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect Immun 75: 1303-1309.
42. Carpena X, Wiseman B, Deemagarn T, Herguedas B, Ivancich A, et al. (2006) Roles for Arg426 and Trp111 in the modulation of NADH oxidase activity of the catalase-peroxidase KatG from Burkholderia pseudomallei inferred from pHinduced structural changes. Biochemistry 45: 5171-5179.
43. Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ (2006) Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc Natl Acad Sci U S A 103: 5526-5530.
44. Ding AH, Nathan CF, Stuehr DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412.
45. Fortier AH, Polsinelli T, Green SJ, Nacy CA (1992) Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, ffector cells, and effector molecules. Infect Immun 60: 817-825.
46. Schneemann M, Schoedon G, Hofer S, Blau N, Guerrero L, et al. (1993) Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 167: 1358-1363.
47. Weinberg JB (1998) Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med 4: 557-591.
48. Fang FC (2004) Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2: 820-832.
49. Annane D, Sanquer S, Sebille V, Faye A, Djuranovic D, et al. (2000) Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 355: 1143-1148.
50. Pham TN, Rahman P, Tobin YM, Khraishi MM, Hamilton SF, et al. (2003) Elevated serum nitric oxide levels in patients with inflammatory arthritis associated with co-expression of inducible nitric oxide synthase and protein kinase C-eta in peripheral blood monocyte-derived macrophages. J Rheumatol 30: 2529-2534.
51. Bosio CM, Elkins KL (2001) Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity. Infect Immun 69: 194-203.
52. Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK (1996) Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun 64: 3288-3293.
53. Brett PJ, Deshazer D, Woods DE (1997) Characterization of Burkholderia pseudomallei and Burkholderia pseudomallei-like strains. Epidemiol Infect 118: 137-148.
54. Brett PJ, Burtnick MN, Snyder DS, Shannon JG, Azadi P, et al. (2007) Burkholderia mallei expresses a unique lipopolysaccharide mixture that is a potent activator of human Toll-like receptor 4 complexes. Mol Microbiol 63: 379-390.
55. Starr T, Ng TW, Wehrly TD, Knodler LA, Celli J (2008) Brucella intracellular replication requires trafficking through the late endosomal/lysosomal compartment. Traffic 9: 678-694.
56. Gowen BB, Fairman J, Smee DF, Wong MH, Jung KH, et al. (2006) Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res 69: 165-172.
57. Chase JC, Bosio CM (2009) Presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun.